<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343052">
  <stage>Registered</stage>
  <submitdate>28/06/2011</submitdate>
  <approvaldate>28/06/2011</approvaldate>
  <actrnumber>ACTRN12611000658910</actrnumber>
  <trial_identification>
    <studytitle>A randomised trial comparing the effect of green-lipped mussel and glucosamine in treating osteoarthritis of the knee and assessing if this correlates to the nutraceuticals improving gut integrity</studytitle>
    <scientifictitle>A Phase-I Randomised, Comparison Pilot Trial Evaluating the Efficacy of Nutraceutical Compounds in patients with Osteoarthritis of the Knee  Therapeutic Outcome Measures Correlated to Gastrointestinal Integrity.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>The University of Queensland HREC 2009000148</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis of the knee</healthcondition>
    <healthcondition>Irritable Bowel Symptoms</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Green-Lipped Mussel extract    3000mg/day

3 capsules taken orally twice per day over 12 weeks</interventions>
    <comparator>Glucosamine sulphate       3000mg/day

3 capsules taken orally twice per day over 12 weeks</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Faecal Microbial Analysis</outcome>
      <timepoint>At baseline before supplementation and at week 12 after commencement of supplements</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The Western Ontario and McMaster Universities Arthritis Index (WOMAC) which measures knee pain, knee stiffness and impaired physical function due to knee osteoarthritis.</outcome>
      <timepoint>baseline and at week 6 and week 12 after commencement of supplements</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Gastrointestinal Symptom Rating Score (GSRS)</outcome>
      <timepoint>Baseline, week 6 and week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Lequesne Index questionnaire which measures knee pain, walking distance and daily living in patients with osteoarthritis of the knee.</outcome>
      <timepoint>baseline and at week 6 and week 12 after commencement of supplements</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SF-12 short form Health Questionnaire</outcome>
      <timepoint>baseline and at week 6 and week 12 after commencement of supplements</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Daily pain score on 5 point likert scale</outcome>
      <timepoint>daily for 12 weeks starting from first day of supplementation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Not taking any form of herbal/multivitamin, fish oil, probiotic, glucosamine or GLM therapy within the past 2 weeks prior to the study enrolment 
- Confirmed osteoarthritis of the knee(s) by appointed Rheumatologist</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Concurrent use of any other investigational product(s);
- Active substance abuse (alcohol or drug dependency);
- Breastfeeding or pregnancy, 
- Allergies to Shellfish (Mollusks and Crustaceans)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation not concealed</concealment>
    <sequence>computerised random number generated</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/06/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>4102</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>The University of Queensland</primarysponsorname>
    <primarysponsoraddress>Research and Innovation Division
Cumbrae-Stewart Building (72)
St Lucia, QLD 4072</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>The Centre for Integrative Clinical and Molecular Medicine, The University of Queensland</fundingname>
      <fundingaddress>The Princess Alexandra Hospital
The Centres for Health Research
Lvl 2, R wing
199 Ipswich rd
Woolloongabba, QLD, 4102</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Aroma NZ</sponsorname>
      <sponsoraddress>12 Senior Place
Bromley
Christchurch 8062</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Bioscreen Medical</othercollaboratorname>
      <othercollaboratoraddress>Bio21 Molecular Science &amp; Biotechnology Institute
Building 404, Room G6
2Park Drive, University of Melbourne,
Parkville, Victoria, 3010</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the trial is to compare the efficacy of a green-lipped mussel (GLM) extract to a glucosamine sulphate preparation in patients with osteoarthritis (OA) of the knee(s) and to determine if gastrointestinal dysfunction (particularly altered gut flora) plays a role in the therapuetic outcomes. Gastrointestinal dysfunction is reported in OA patients and preliminary data has shown GLM significantly improves gut function. This comparative trial will investigate the gut flora in patients before and after supplementation to see if the nutaceuticals are therapeutically affecting gut flora and function as a mechanism of action of decreasing inflammation and improving pain and stiffness indices in OA patients.</summary>
    <trialwebsite />
    <publication>Coulson S, Vecchio P, Masci P, Vitetta L. GreenLipped Muscle Extract and GIT Function in Patients Diagnosed with OA of the Knee. AIMA International Integrative Conference 2009, Abstract Presentation.

Coulson S, Vecchio P, Masci O, Vitetta L.  A randomized phase-I/pilot comparison trial evaluating the efficacy of nutraceutical compounds in patients with osteoarthritis of the knee  therapeutic outcome measures correlated to gastrointestinal integrity. International conference on the science of nutrition in medicine and healthcare 2011; Scientific stream and accepted abstracts, pg 80.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The University of Queensland Human Research Ethics Committee</ethicname>
      <ethicaddress>The University of Queensland
Research &amp; Research Training Division
Cumbrae-Stewart Building (72)
St Lucia 4072</ethicaddress>
      <ethicapprovaldate>22/02/2011</ethicapprovaldate>
      <hrec>2009000148</hrec>
      <ethicsubmitdate>1/02/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>samantha coulson</name>
      <address>The Princess Alexandra Hospital
The Centres for health research
Lvl 2, R wing
Ipswich Rd
Woolloongabba 4102
QLD</address>
      <phone>+61 07 3176 5273</phone>
      <fax>+61 07 3176 6858</fax>
      <email>s.coulson@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Samantha Coulson</name>
      <address>The Princess Alexandra Hospital
The Centres for health research
Lvl 2, R wing
Ipswich Rd
Woolloongabba 4102
QLD</address>
      <phone>+61 07 3176 5273</phone>
      <fax>+61 07 3176 6858</fax>
      <email>s.coulson@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>samantha coulson</name>
      <address>The Princess Alexandra Hospital
The Centres for health research
Lvl 2, R wing
Ipswich Rd
Woolloongabba 4102
QLD</address>
      <phone>+61 07 3176 5273</phone>
      <fax>+61 07 3176 6858</fax>
      <email>s.coulson@uq.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>